glp-1 and insulin resistance Favorable Effects of Receptor Agonist against Pancreatic β-Cell Glucose Toxicity the Development of Arteriosclerosis: “The Earlier, the Better” in Therapy with Incretin-Based Medicine Adipose Tissue: A Novel Target

9,12 Additionally, GLP-1RAs activate nitric oxide (NO) synthase expressed in Schlemms canal and the trabecular meshwork, increasing NO production to reduce trabecular meshwork contraction, improving aqueous outflow

Efficacy and safety of an expanded dulaglutide dose range: a phase 2, placebo-controlled trial in patients with type 2 diabetes using metformin

To remove the effects of pauses in medication or low average medication dose, several thresholds for MPR were used: MPR 0.5, MPR 0.75, and MPR 0.95

Published clinical trial data from the SURMOUNT trials has shown pronounced average effects on body weight in some trial populations

Over the last few years, GLP-1 medications have been approved with indications strictly for weight loss and chronic weight management by the U.S